Geron Investors Ink $24M Deal Over Cancer Study Results
By Donald Morrison ( September 6, 2022, 6:25 PM EDT) -- Geron Corp. investors have reached a $24 million settlement resolving their claims that the biotechnology company and its chief executive officer hid negative results of a clinical trial for a blood cancer drug while earning millions of dollars in a stock offering, according to a recently filed motion for approval of the deal....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.